CN108136048A - 左旋多巴的系统合成和调节 - Google Patents

左旋多巴的系统合成和调节 Download PDF

Info

Publication number
CN108136048A
CN108136048A CN201680045737.2A CN201680045737A CN108136048A CN 108136048 A CN108136048 A CN 108136048A CN 201680045737 A CN201680045737 A CN 201680045737A CN 108136048 A CN108136048 A CN 108136048A
Authority
CN
China
Prior art keywords
seq
expression system
polypeptide
group
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680045737.2A
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·麦克唐纳德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mi Odo Ba Co Ltd
Original Assignee
Mi Odo Ba Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mi Odo Ba Co Ltd filed Critical Mi Odo Ba Co Ltd
Publication of CN108136048A publication Critical patent/CN108136048A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/16—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
    • C12Y114/16002—Tyrosine 3-monooxygenase (1.14.16.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04016—GTP cyclohydrolase I (3.5.4.16)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/03—Carbon-oxygen lyases (4.2) acting on phosphates (4.2.3)
    • C12Y402/03012—6-Pyruvoyltetrahydropterin synthase (4.2.3.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C12Y114/13162—2,5-Diketocamphane 1,2-monooxygenase (1.14.13.162), i.e. camphor 1,2-monooxygenase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680045737.2A 2015-08-03 2016-08-01 左旋多巴的系统合成和调节 Pending CN108136048A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562200151P 2015-08-03 2015-08-03
US62/200,151 2015-08-03
PCT/EP2016/068315 WO2017021359A1 (en) 2015-08-03 2016-08-01 Systemic synthesis and regulation of l-dopa

Publications (1)

Publication Number Publication Date
CN108136048A true CN108136048A (zh) 2018-06-08

Family

ID=56682101

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680045737.2A Pending CN108136048A (zh) 2015-08-03 2016-08-01 左旋多巴的系统合成和调节

Country Status (8)

Country Link
US (1) US20190032079A1 (enExample)
EP (1) EP3331570A1 (enExample)
JP (1) JP2018522595A (enExample)
KR (1) KR20180034467A (enExample)
CN (1) CN108136048A (enExample)
CA (1) CA2992511A1 (enExample)
RU (1) RU2018104098A (enExample)
WO (1) WO2017021359A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112752851A (zh) * 2018-07-27 2021-05-04 加利福尼亚大学董事会 胸主动脉瘤的生物标志物
CN113874513A (zh) * 2019-03-13 2021-12-31 世代生物公司 非病毒dna载体及其用于表达fviii治疗剂的用途
CN115003804A (zh) * 2019-08-12 2022-09-02 治疗基因有限责任公司 基因构建体
WO2025045033A1 (zh) * 2023-08-28 2025-03-06 康霖生物科技（杭州）有限公司 用于治疗帕金森病的基因治疗载体及其用途

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
WO2019210187A1 (en) * 2018-04-26 2019-10-31 The University Of North Carolina At Chapel Hill Methods and compositions for treatment of hemophilia
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
JP7541027B2 (ja) * 2019-04-08 2024-08-27 ジェネトン 筋肉発現のためのハイブリッドプロモーター
IL294238A (en) * 2019-12-24 2022-08-01 Asklepios Biopharmaceutical Inc Nucleic acid regulatory sequences
WO2021165350A1 (en) * 2020-02-18 2021-08-26 Vrije Universiteit Brussel Novel combination of nucleic acid regulatory elements and methods and uses thereof
EP4114469A1 (en) * 2020-03-04 2023-01-11 Poseida Therapeutics, Inc. Compositions and methods for the treatment of metabolic liver disorders
AU2021263938A1 (en) * 2020-04-29 2022-10-20 Saliogen Therapeutics, Inc. Compositions and methods for treatment of familial hypercholesterolemia and elevated low-density lipoprotein cholesterol
WO2022013407A1 (en) * 2020-07-15 2022-01-20 Danmarks Tekniske Universitet Therapeutic microbes
GB2601752A (en) * 2020-12-08 2022-06-15 Maavrx Ltd Expression vector
CN117897492A (zh) * 2021-08-04 2024-04-16 吉尼松公司 用于肌肉和cns中的基因表达的杂合启动子
EP4405492A4 (en) * 2021-09-24 2025-07-09 Univ Duke COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING GLUTARIC ACIDURIA TYPE I

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020096181A (ko) * 2001-06-18 2002-12-31 박영식 재조합 대장균에 의한 테리딘 화합물의 제조방법
US20090111106A1 (en) * 2000-10-06 2009-04-30 Kyri Mitrophanous Vector System
CN102695526A (zh) * 2009-11-09 2012-09-26 吉恩波多治疗股份公司 用于神经元特异性的体内连续dopa合成的新型病毒载体构建体
WO2013061076A1 (en) * 2011-10-28 2013-05-02 Oxford Biomedica (Uk) Limited Construct

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO1987000201A1 (en) 1985-07-05 1987-01-15 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
EP0378576B1 (en) 1987-09-11 1995-01-18 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5677158A (en) 1995-06-07 1997-10-14 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6451306B1 (en) 1998-04-15 2002-09-17 The Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
JP2002516295A (ja) 1998-05-27 2002-06-04 アビジェン， インコーポレイテッド Ａａｖベクターの対流増加送達

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090111106A1 (en) * 2000-10-06 2009-04-30 Kyri Mitrophanous Vector System
KR20020096181A (ko) * 2001-06-18 2002-12-31 박영식 재조합 대장균에 의한 테리딘 화합물의 제조방법
CN102695526A (zh) * 2009-11-09 2012-09-26 吉恩波多治疗股份公司 用于神经元特异性的体内连续dopa合成的新型病毒载体构建体
US20150065560A1 (en) * 2009-11-09 2015-03-05 Genepod Therapeutics Ab Novel viral vector construct for neuron specific optimized continuous dopa synthesis in vivo
WO2013061076A1 (en) * 2011-10-28 2013-05-02 Oxford Biomedica (Uk) Limited Construct

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHIU YH ET AL.: "Homo sapiens 6-pyruvoyltetrahydropterin synthase (PTS), mRNA NCBI Reference Sequence: NM_000317.2", 《GENBANK》 *
CRAIG BENCSICS ET AL.: "Double Transduction with GTP Cyclohydrolase I and Tyrosine Hydroxylase Is Necessary for Spontaneous Synthesis of L-DOPA by Primary Fibroblasts", 《THE JOURNAL OF NEUROSCIENCE》 *
GRIMA,B. ET AL.: "Human mRNA for tyrosine hydroxylase (HTH-1) GenBank: X05290.1", 《GENBANK》 *
NOMURA,T. ET AL.: "Human GTP cyclohydrolase I mRNA, complete cds GenBank: U19523.1", 《GENBANK》 *
陈树宝: "《儿科学 新理论与新技术》", 31 January 1997, 上海科技教育出版社 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112752851A (zh) * 2018-07-27 2021-05-04 加利福尼亚大学董事会 胸主动脉瘤的生物标志物
CN113874513A (zh) * 2019-03-13 2021-12-31 世代生物公司 非病毒dna载体及其用于表达fviii治疗剂的用途
CN115003804A (zh) * 2019-08-12 2022-09-02 治疗基因有限责任公司 基因构建体
WO2025045033A1 (zh) * 2023-08-28 2025-03-06 康霖生物科技（杭州）有限公司 用于治疗帕金森病的基因治疗载体及其用途

Also Published As

Publication number Publication date
WO2017021359A1 (en) 2017-02-09
JP2018522595A (ja) 2018-08-16
CA2992511A1 (en) 2017-02-09
EP3331570A1 (en) 2018-06-13
RU2018104098A3 (enExample) 2020-08-10
KR20180034467A (ko) 2018-04-04
RU2018104098A (ru) 2019-09-06
US20190032079A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
CN108136048A (zh) 左旋多巴的系统合成和调节
JP7601916B2 (ja) 蝸牛および前庭細胞に核酸を送達するための物質および方法
AU2016232146B2 (en) Optimized liver-specific expression systems for FVIII and FIX
CN111344395B (zh) 产生经修饰的自然杀伤细胞的方法及使用方法
KR102729768B1 (ko) 트랜스제닉 선택 방법 및 조성물
AU2017323629B2 (en) PD-1 homing endonuclease variants, compositions, and methods of use
AU774643B2 (en) Compositions and methods for use in recombinational cloning of nucleic acids
AU2019261438B2 (en) Expression of FOXP3 in edited CD34+ cells
KR102745604B1 (ko) Glp-1 및 대사성 질환 치료용 조성물에서 이의 용도
AU2016229000B2 (en) Recombinant Glut1 adeno-associated viral vector constructs and related methods for restoring Glut1 expression
CN112313334A (zh) 用以编辑血红蛋白相关突变的同源定向修复模板设计和递送
KR20180097631A (ko) 핵산을 와우 및 전정 세포에 전달하기 위한 물질 및 방법
KR102628872B1 (ko) 세포의 증식을 제어하기 위해 세포 분열 좌위를 사용하기 위한 도구 및 방법
AU2017277647B2 (en) Engineered viral vector reduces induction of inflammatory and immune responses
AU2018254529B2 (en) Therapeutic genome editing in Wiskott-Aldrich syndrome and X-linked thrombocytopenia
KR20210151785A (ko) 비바이러스성 dna 벡터 및 fviii 치료제 발현을 위한 이의 용도
KR20240022575A (ko) 아머링된 키메라 수용체 및 이의 사용 방법
CN112312931A (zh) X连锁高IgM综合征的治疗性基因组编辑
KR20220023962A (ko) 파브리병을 치료하기 위한 조성물, 디바이스 및 방법
CN115298307A (zh) 核酸调节元件的新组合及其方法和用途
HK40082332A (zh) 使用细胞分裂基因座控制细胞增殖的工具和方法
HK40044016A (en) Expression of foxp3 in edited cd34+ cells
HK40024481A (en) Therapeutic genome editing in wiskott-aldrich syndrome and x-linked thrombocytopenia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180608